An assessment of efficacy and safety of combined inhaled therapy of bronchial asthma patients
Abstract
The aim was to study efficacy and safety of combined drug fomroterol/budesonide (Simbicort Turbuhaler) in various doses in bronchial asthma patients.
Fifteen patients (7 females and 8 males) with controlled exacerbation of moderate atopic asthma aged 43 to 66 (51.1 in average) were observed. The first 2 weeks the patients used short-acting β2-agonists if needed. Then they received Simbicort Turbuhaler 2 inhaled doses twice a day for 4 weeks and 1 inhaled dose twice a day for the following 8 weeks. Clinical sighs, quality of life (the AQLAQ questionnaire), lung function parameters (peakflowmetry, FEV1) were assessed during the treatment period. Hydrogen peroxide (H202) concentration at the exhaled breath condensate was measured spectrophotometrically to evaluate the airway inflammation activity. The plasma cortizol concentration was determined with an immunoenzyme assay.
A reliable growth of the peak expiratory flow volume was noted at the 1st day of the treatment in 3 min after the inhalation of 2 doses of Simbicort Turbuhaler and kept for 12 h. During the further treatment with various doses of this drug a positive dynamics in the clinical sighs and the quality of life was noted. A significant increase in the lung function values was observed at the 14th day of the treatment. A considerable reduction in the H202 concentration at the exhaled breath condensate was found at the end of the 3rd month of the treatment which is probably due to the anti-inflammatory activity of the drug. The plasma cortizol level did not change.
The data obtained show the combination formoterol/budesonide (Simbicort Turbuhaler) to demonstrate a rapid action. It can be used to achieve and maintain an individual control for moderate asthma. The positive effect was distinctly reached to the end of the 3rd month of the treatment that confirms the need of long-term application of the combined drugs. Therapeutic doses of Simbicort Turbuhaler were well-tolerated and did not give adverse effects.
About the Authors
A. V. Yemelyanov
Санкт-Петербургский государственный медицинский университет им.акад.И.П.Павлова
Russian Federation
Russian Federation
T. E. Yelizarova
Санкт-Петербургский государственный медицинский университет им.акад.И.П.Павлова
Russian Federation
Russian Federation
References
1. Antzak A., Nowak D., Shariati В. et al. Increased hydrogen peroxide and thiobarbituric acid-reactive products in expired breath condensate of asthmatic patients. Eur. Respir. J. 1997; 9 (6): 1235-1241.
2. Barnes P. Scientific rationale for inhaled combination therapy with long-acting p2-agonists anc^ corticosteroids. Ibid. 2002; 19 (1): 182-191.
3. Barnes P.J., Pedersen S., Busse W.W. Efficacy and safety of inhaled corticosteroids. New development. Am. J. Respir. Crit. Care Med. 1998; 157 (3, pt 2): 1S-53S.
4. Bousquet J., Jeffery P.K., Busse W.W. et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Ibid. 2000; 161 (5): 1720-1745.
5. Emelyanov A., Fedoseev G., Abuduani A bulim ity et al. Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients. Chest 2001; 120 (4): 1136-1139.
6. Gallati H., Pracht I. Horseradish peroxidase: kinetic studies and optimisation of peroxide activity determination using the substrates H20 2 and 3,3’, 5,5’-tetramethybenzidine. J. Clin. Chem. Clin. Biochem. 1985; 23 (8): 453-460.
7. Global Initiative for asthma. — NHLB/W HO workshop report. National Heart Lung Blood Institute, Publication number 95-3659, revised 2002.
8. Horvath I., Donnely L.E., Kiss A. et al. Combined use of exhaled hydrogen peroxide and nitric oxide in monitoring asthma. Am. J. Respir. Crit..Care Med. 1998; 158 (4): 1042-1046.
9. Juniper E.F., Guyatt G.H., Ferrie P.J., Griffith L.E. Measurement quality of life in asthma. Am. Rev. Respir. Dis. 1993; 147 (4): 832-838.
10. McGavin J.K., Goa K.L., Jarvis B. Inhaled budesonide/ formoterol combination. Drugs 2001; 61 (1): 71-78.
11. Suissa S., Ernst P., Benayoun S. et al. Low-dose of inhaled corticosteroids and prevention of death from asthma. N. Engl. J. Med. 2000; 343 (5): 332-336.
Review
For citations:
Yemelyanov A.V., Yelizarova T.E. An assessment of efficacy and safety of combined inhaled therapy of bronchial asthma patients. PULMONOLOGIYA. 2003;(1):63-66. (In Russ.)
Views:
201
Email this article 